‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders

Lisa Parker 1,2, Quinn Grundy 3, Alice Fabbri 1,3, Barbara Mintzes 1, Lisa Bero 1,4

ABSTRACT

Objectives To study how patient groups that accept pharmaceutical industry money perceive and manage the risk of undue influence from their sponsors.

Design Empirical ethics approach using a qualitative interview study.

Setting The Australian patient group sector.

Participants 27 participants from 23 patient groups, purposively recruited for diversity of group characteristics (degree of pharmaceutical industry funding, health focus, location) and participant role (staff, board members).

Analysis Interview data were transcribed and read repeatedly to identify concepts and patterns in the data. These were grouped into conceptual categories that described and explained the findings. We used an inductive analytical approach to identify important themes and concepts in the data.

Results Participants in this study described how the patient group sector receives pressure from pharmaceutical company funders to act in ways that prioritise company interests. Groups worked to try and protect their credibility and ability to act in ways of their own choosing using practical rules or ‘lines in the sand’ about industry funding activities. They were grouped around the dominant topics of: sponsor exclusivity, brand marketing, agenda setting, advocacy and content of group activities. Lines in the sand were largely experience-driven and ethically informed; they varied between groups. There was also variable transparency among groups about financial interactions with pharmaceutical companies.

Conclusions It is important to know about patient group practices around pharmaceutical industry funders as this allows public scrutiny about the adequacy of such practices. Inadequate strategies may mean that funders can influence patient groups in ways that do not necessarily prioritise the interests of members. We found that groups differed in their approach, with little independent external guidance to inform responses to commonly encountered types of influence. Inadequate transparency limits the ability of the public to make informed assessments about the risk of bias over the activities of groups that accept industry funding.

INTRODUCTION

Patient groups are important stakeholders in the health sector. Their roles include supporting patients, educating their members and health professionals, contributing to guideline development, funding medical research and advocating in relation to health services including affordable access to drugs. Patient groups commonly receive money from the pharmaceutical industry. For example, a Finnish study showed that 71% of 55 surveyed groups received pharmaceutical company money10 and a recent study of 104 wealthy US patient groups showed that 83% received funding from drug, device and biotechnology companies.

There is concern that acceptance of pharmaceutical industry money might compromise the independence of patient groups. This is important because a compromised patient group voice might end up furthering industry interests rather than those of their membership, for example, by selectively providing advice and lobbying for services and products that are also in sponsors’ interests, and remaining silent on issues such as

Strengths and limitations of this study

► This interview study draws on comprehensive data from patient groups with diverse industry funding experiences, disease focus and jurisdiction.

► This is the first empirical study to focus on how patient groups manage risks to independence.

► The study was limited to the Australian setting.

► We spoke to staff and board members from patient groups but did not speak to individual patient advocates.

► Participants may have spoken selectively about their group’s interactions with the pharmaceutical industry in a way that supported the concept of an independent patient group sector.
medication safety or high prices. In this paper, we draw on Jonathan Marks’ analysis of public–private partnerships to explore financial interactions between patient groups and the pharmaceutical industry.\(^1\) We draw on his broad conception of independence, to mean patient group judgements, decisions, actions and beliefs that prioritise the interests of group members and the wider patient community, rather than the interests of commercial sponsors. While patient groups and the pharmaceutical industry may share interests in matters such as ready access to therapeutically useful drugs, there may be divergence between the interests of the two sectors in other important topics such as use of drugs that have poor side effect profiles, questionable therapeutic benefit and unreasonable cost.\(^6\)\(^9\)\(^10\) Several studies have shown an association between industry funding and patient groups’ positions on health and policy issues.\(^11\)\(^13\) For example, patient groups in the USA that advocated to maintain ready public access to opioids were more likely to be funded by opioid manufacturers than groups that advocated for restricted access.\(^11\) This is part of the increasingly recognised link between industry sponsorship of healthcare stakeholders and outcomes that favour the sponsor’s interests,\(^16\) a pattern that is being repeated across clinical practice,\(^17\)\(^18\) medical education,\(^19\)\(^20\) guideline development\(^21\) and medical research.\(^22\) There is urgency about identifying and managing financial conflicts of interests in the health sector in order to protect the public’s interests, including their health.

Interactions between the pharmaceutical industry and patient groups may fall under the jurisdiction of self-regulatory codes of practice. Pharmaceutical trade associations around the world have codes of practice regulating member company relationships with the health sector, including with patient groups.\(^23\)\(^24\) These codes vary slightly depending on the jurisdiction—for example, codes in Europe, the UK and Australia require member companies to publicly disclose funding to patient groups, but this is not the case in the USA.\(^25\) Not all pharmaceutical companies are members of their local trade organisation and therefore not all companies are bound by these self-regulatory codes. In addition, umbrella organisations that provide support and resources to patient groups may have codes of practice that offer guidance on relationships with pharmaceutical company funders, often coauthored with the industry.\(^26\)\(^27\)

There is a paucity of empirical research on how patient groups think about the possible impact of pharmaceutical industry sponsorship on their group’s independence and how they act to protect their independence. Limited data suggest that at least some groups that accept pharmaceutical company money perceive a threat to their independence,\(^5\)\(^28\)\(^31\) and that some, but not all groups, adopt strategies such as transparency around funding, and formal conflict of interest policies.\(^1\)\(^4\)\(^29\)\(^31\)\(^33\) There is a lack of comprehensive, up-to-date information about other practices that patient groups may adopt to protect themselves against industry influence. We have previously written about the nature of patient group interactions with the pharmaceutical industry, describing a range of different attitudes and experiences articulated by people in patient group leadership roles.\(^30\) This paper sharpens our focus on the patient group—pharmaceutical company nexus, looking very particularly at the practical, day-to-day management of sponsor influence. This information is important for public scrutiny of current industry and group practices, and to allow groups to learn from each other when striving for best practice.

The impetus for the study was previously identified ethical concerns about pharmaceutical industry funding of patient groups.\(^7\)\(^34\) We undertook an empirical study to explore these concerns and to stimulate and inform conversations about how best to maintain patient group independence from the pharmaceutical industry into the future. Our research questions were:

- What are the views of people working in patient groups about the risk of harm to their independence from accepting pharmaceutical industry money?
- What practices and policies are currently in use by patient groups to mitigate these risks?

**METHODS**

**Design**

We adopted an empirical ethics approach,\(^35\) drawing on an emerging methodological discipline that combines empirical study with ethics theory to explore and comment on a matter of ethical importance. This approach assumes that empirical data and theoretical reflection can each inform the other to enable deep engagement with, and guidance for, a complex ethical topic.\(^36\) Using this approach, we designed an empirical study to identify what was happening in relation to our general topic of interest (pharmaceutical industry funding of patient groups). We used our knowledge of theoretical and applied ethics, drawing particularly on Marks’ conceptions of independence and integrity\(^8\) to inform our research questions, specific lines of inquiry and analysis. Ultimately, we intended our findings about what is happening to inform our recommendations and contribute towards public discussion on the ethical question of what should be happening. For the empirical component of the work, we used qualitative research methods, which are well suited to exploring social ideas and behaviours such as perceptions about risk and practices around managing conflicts of interest.\(^37\) We conducted individual interviews, with sampling, recruitment and data collection methods that were suited to our research questions.\(^38\)\(^40\)

Our research team academic experts in industry influence in health (LB, QG, LP, AF and BM), health professionals (QG in nursing, and LP and AF in medicine), and experienced qualitative researchers (QG and LP). Our diverse experience and expertise enabled us to view and analyse the data from many different perspectives. We report our methods in keeping with the Consolidated criteria for Reporting Qualitative research guideline.\(^41\)
Participant population

We conducted one-on-one interviews with key people working in patient groups who were familiar with their group’s experiences and policies around funding and interactions with the pharmaceutical industry. We used the Australian patient group sector as a geographical case study for two reasons. First, we had access to information about pharmaceutical industry funding of patient groups, since Medicines Australia, the trade organisation for Australia’s pharmaceutical industry, requires all its members to adhere to a Code of Conduct that states companies must publicly disclose their spending on patient groups. Second, Australia has a well-established patient group sector, similar to that in other developed countries such as the UK, the USA, Canada and throughout Europe. Some groups in Australia focus on specific health conditions and others focus more broadly on health service delivery for current or future patients (‘health consumers’) and their communities.

We conducted a non-exhaustive list of Australian patient groups using several sources. First, we extracted a list of the 230 Australian patient groups that had received pharmaceutical industry funding between 2013 and 2016, drawn from a database that our research group has previously created. This database collates the publicly available information about pharmaceutical company spending on patient groups, as required for all Medicines Australia members. The database is freely accessible at http://dx.doi.org/10.25910/5bc67fed51798 Second, we included all seven of the peak national and regional (state and territory) patient group organisations, which are focused on general health service matters. Third, we accessed the 53 patient groups listed as members on the website of the peak national patient group organisation, Consumers Health Forum (https://chf.org.au/our-members) on 15 November 2017 and searched for organisations not already identified through our other methods. This provided an additional 21 groups (running total 258). We also followed up suggestions from previous participants (snowball sampling) and searched via Google for groups linked to those previously identified (eg, groups with similar disease focus but serving different regions). When considering recruitment from those groups that did not appear on the database we checked for evidence of pharmaceutical industry funding on groups’ websites (eg, pharmaceutical logos, sponsorship lists, annual financial reports).

Sampling and recruitment

We sampled purposively, aiming for participants with a range of experiences around industry funding. We reasoned that participant experiences were likely to be associated with overall levels of pharmaceutical company interest in contacting, funding and interacting with patient groups. We also considered that pharmaceutical interest, and therefore, participant experience might be associated with patient group focus, particularly in relation to specific diseases or pathological processes for which there may or may not be new products currently under patent, and the perceived reach or influence of the group (eg, local vs national jurisdiction.) Therefore, we sought to recruit participants from groups with differing characteristics across a range of variables such as: level of pharmaceutical industry funding, group focus (specific disease, general health service matters), jurisdiction (local, national). We also aimed to recruit from patient groups focusing on different types of disease and body system and different pathological processes (see online supplemental file 1). This was because we knew from clinical experience that new medications tended to coalesce around particular illnesses and/or pathophysiological processes. As such, we reasoned that some types of groups might be more likely than others to receive overtures from pharmaceutical companies with new drugs to market. We wanted to hear from groups representing current marketing opportunities for industry and also those that were not. We drew up a rough list of body systems and pathological processes (see online supplemental file 1) and tried to ensure that our final participant group included a reasonable spread across both lists. We also aimed to speak with participants holding experience interacting with pharmaceutical industry funders or developing and implementing organisational policy on pharmaceutical industry funding. As such we sought out both senior staff members and board members.

We began by targeting a few patient groups across a range of characteristics including disease/pathological process and funding status. Our first recruitment email went out to just four groups. As data collection proceeded, we focused on recruiting from patient groups with characteristics that we had not previously managed to recruit from and for participants with different roles. Our recruitment emails were sent directly to the Chief Executive Officers (CEOs) and/or Board Presidents if those contact details were publicly available, or if not, to the generic email address of our target patient groups.

We contacted 55 potential participants from 49 patient groups by email using details available in the public domain. Recruitment, data collection and analysis were conducted iteratively so that each could inform the other. Recruitment evolved as the study progressed to ensure diversity of participant characteristics and data.

Data collection

LP conducted semistructured interviews with participants, explaining her research interest in how health sector workers think about and manage industry influence, and professional experience as a medical clinician. She asked about participants’ views and experiences with industry funding and how possible conflicts of interest were managed during their role in the current group (see online supplemental file 2). The interviews were conducted at a time and location suitable for the participant, face to face or over the phone. There was no observable difference in the quality of the data from phone interviews, and using this method enabled us
to include participants from outside of the local area. All participants gave informed consent. The interviews were recorded, professionally transcribed and deidentified. Pseudonyms are used in this paper to protect participant confidentiality.

Analysis

Our analysis was informed by our prior reading of the literature on patient group interactions with the pharmaceutical industry and the theoretical concepts explored by Marks, particularly ‘institutional independence’. We used widely practised qualitative research methods involving field notes, coding and writing memos about emerging topics of interest. LP wrote field notes after each interview that captured contextual information, initial impressions and reflexive thoughts. All transcripts and field notes were imported into NVivo software. LP read the field notes and early transcripts multiple times and developed an initial coding scheme generated from background knowledge on industry relationships with patient groups, theoretical ethics concepts and the emerging data. The coding scheme was used on selected transcripts (chosen for their conceptual interest and variety) by all members of the research team. Interpretations were compared at a team meeting and informed an updated coding scheme, which LP then applied to all transcripts (see online supplemental file 3). The team read and coded the same selected manuscripts from remaining interviews (again chosen for conceptual interest and variety) and exchanged ideas at fortnightly meetings. Selected codes were translated and expanded on by LP into memos that included theoretical reflection and ethical concepts. For example, in memos on independence we sought to compare and contrast how groups discussed and enacted limits to acceptable practice. Memos were cross-checked against the raw data to ensure accuracy of reporting and analytical interpretation.

Patient and public involvement

One member of the research team (BM) has had extensive involvement with women’s health groups and consumer groups generally. She is a current member of Health Action International. We also coconvened a patient group stakeholder meeting in conjunction with one national and one state health consumer organisation in March 2020, to discuss and build on our research work.

RESULTS

We sent 55 recruitment requests to individuals and generic email addresses associated with 50 different groups. Thirty-six were from industry-funded groups and 19 from groups without industry funding. LP interviewed 27 people (19 women, 8 men) from 23 groups, including 17/36 (47.2%) people approached from industry funded groups and 10/19 (52.6%) of people approached from groups without industry funding. The reasons for not interviewing 28 people included: non-response to recruiting email (19) or follow-up emails (4), refusal (4) and email-send failure (1). We had more recruiting success from individualised emails than from generic emails: 7/10 (70%) emails to targeted staff members and 4/7 (57%) targeted Board members resulted in interviews compared with 15/38 (39%) generic patient group emails. Overall, two-thirds of participants were from industry funded groups, most of which were focused on specific health conditions, either with national or regional jurisdiction (see table 1 for details). The interviews were conducted between October 2017 and October 2018; they lasted 25–95 min (average 60 min). We continued sampling until we were confident that we had spoken with a wide range of participants and were no longer hearing new information about patient group interactions with pharmaceutical industry funders.

Participants talked about receiving pressure from the pharmaceutical industry to act in particular ways. They described strategies to maintain their independence, including paying attention to issues of: sponsor exclusivity, brand marketing, agenda setting, advocacy partnerships and content of patient group communications and events. We identified variation between patient groups in where they drew the line between acceptable and unacceptable practices relating to these topics. We also identified variation in patient group practices and policies around transparency of pharmaceutical industry sponsorship. We discuss all of these matters in more detail below.

Undue influence from pharmaceutical industry sponsors

Participants described how patient groups were pressured to act in ways that aligned with the interests of a pharmaceutical company funder. This meant that groups were not necessarily working towards their own, independently identified priorities. For example, one participant described how her group ended up producing and promoting an information pack at the request of a pharmaceutical company funder. Accepting money for this work meant being engaged in an industry-benefitting activity rather than pursuing the group’s own prioritised goals. The job was seen by the participant as being incidental to her group’s core mission and therefore resulting in opportunity costs, ‘it … just wasn’t … the best use of our time.’ [Sally, CEO].

Groups also received pressure to act in ways that ran directly counter to their own interests. Participants described how company personnel sought to dictate the content of patient group communications and outputs. For example, one participant spoke about a company trying to control the content of an education seminar her group was running, and another recalled how a company representative had tried to stop a story in a patient group publication she was editing. Participants acknowledged that this kind of behaviour from funders could mean that groups were unable to provide people with independent support and advice, including being unable to inform


Open access
patients about medications that were not manufactured by their pharmaceutical funders.

Some participants were aware of the power dynamics of the sponsor relationship, describing how budgetary pressures meant it was hard to refuse industry money even if it meant acting in ways they might not have otherwise chosen. In contrast, other participants did not perceive themselves or their group to be at risk of undue influence from pharmaceutical funders because, they reasoned, their group’s actions could not be of any commercial benefit to the company. For example, participants stated they could not further company interests because they did not perceive their group as having any power to influence drug prescribing or much influence over the government’s drug subsidy scheme.

Similarly, many participants had no concerns about promoting industry-funded research, because they felt that this was about science without any elements of industry marketing. For example, Denise (board member) said she saw no issue with accepting money from a company to fund ‘a particular doctor to go to [her group’s] conference and talk about the results of the [company-funded] trial that was close to being finished … Because, I mean, the results of the trial are the result, you know, like, it’s a scientific presentation, it’s not a marketing presentation.’ There was no perception that discussion of industry-funded science research could be used by a company as a marketing exercise.

Regardless of their views on the risk of undue influence from pharmaceutical company sponsors, most

---

Table 1 Characteristics of invitees, including participants and those invited that did not participate

<table>
<thead>
<tr>
<th>Invitee’s patient group focus</th>
<th>Individuals interviewed (n=27)</th>
<th>Individuals invited but not participating (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General health services</strong></td>
<td>6 (22.2)</td>
<td>2 (7.1)</td>
</tr>
<tr>
<td><strong>Specific disease or health condition</strong></td>
<td>21 (77.8)</td>
<td>26 (92.9)</td>
</tr>
<tr>
<td>Body system of specific health condition</td>
<td>Multisystem 5, musculoskeletal 4, neurological 3, non-specific 3, renal 2, sensorineural 2, dermatological 1, respiratory 1,</td>
<td>Haematological 4, endocrine 4, gastrointestinal 4, mental health 3, multisystem 3, neurological 2, women’s health 2, sensorineural 2, dermatological 1, non-specific 1, respiratory 1,</td>
</tr>
<tr>
<td>Pathological process of specific health condition</td>
<td>Non-specific 6, degenerative 4, cancer 3, genetic 3, infective 2, inflammatory 1, immunological 1, other pathological processes 1</td>
<td>Non-specific 9, cancer 5, inflammatory 4, genetic 5, infective 3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invitee’s patient group geographical jurisdiction</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National</strong></td>
<td>15 (55.6)</td>
<td>19 (67.8)</td>
</tr>
<tr>
<td><strong>Regional†</strong></td>
<td>12 (44.4)</td>
<td>9 (32.1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level of pharmaceutical industry funding ($A)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Top quartile ($A103 001**–$A4 107 981)†‡</td>
<td>13 (48.1)</td>
<td>15 (53.6)</td>
</tr>
<tr>
<td>Mid to lowest quartiles ($A&lt;80–$A103 000)‡</td>
<td>4 (14.8)</td>
<td>4 (14.3)</td>
</tr>
<tr>
<td>No pharmaceutical industry funding§</td>
<td>10 (37.0)</td>
<td>9 (32.1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participant role in group</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff-CEO (including acting)</td>
<td>19 (70.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Staff, other¶</td>
<td>4 (14.8)</td>
<td>NA</td>
</tr>
<tr>
<td>Board member</td>
<td>4 (14.8)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Values are numbers (percentages) unless stated otherwise.  
*The four groups from which two participants were interviewed had the following characteristics: (1): general consumer health focus, regional group, no pharmaceutical industry funding; (2,3): disease-specific focus, national group, top-quartile pharmaceutical industry funding; (4) disease specific focus, regional group, mid-quartile funding.   
†Regional groups are based in specific Australian states or territories and serve members living within those regions; most are affiliated with a national group with the same health focus but have separate funding sources.  
‡Group’s position in list of patient groups that received money from the pharmaceutical industry, as listed in our database of funding disclosed by Medicines Australia members during the years 2013–2016 inclusive.  
§Not listed on our database of disclosed pharmaceutical funding of consumer health groups and no obvious declaration of pharmaceutical funding on group website.  
¶Research manager, secretary, fundraising manager.  
**£54 300; €63 600‡£54 300; €63 600.  
CEO, Chief Executive Officer; NA, not applicable.
participants felt that accepting pharmaceutical industry money carried some risk of damage to the public’s perception of their group. They were worried that the public might assume their group was working for the benefit of sponsors, rather than as an independent body engaging in support, education and activism for the benefit of patients and carers. Participants took the risk of reputational damage very seriously and always considered this when making decisions about accepting pharmaceutical company money. As Alan (CEO) said, ‘If we take funding (we think about), ‘Does it compromise our credibility?’. We guard that very jealously… our credibility is probably our most important asset.’

Patient group independence

All participants talked about the importance to their group of being independent from the pharmaceutical industry. For participants, being independent meant the group having total control over their own activities and priorities and not letting funding bodies dictate action or set preferences. For example, Fiona (CEO) spoke about making sure her group was ‘driving the agenda’ rather than being ‘driven by the corporate action.’ Many participants also spoke about independence in terms of receiving (or at least being open to receiving) funding from multiple sources, explaining that if their group was willing to accept money from more than one funder then it clearly could not be a mouthpiece for any single sponsor. This explanation was also given to members of the public and pharmaceutical companies that accused a patient group of being ‘in the pockets’ of one (competitor) company: ‘We contact every single pharmaceutical company … I want to be very clear … that everyone has an equal opportunity to partner with us and if they choose not to, that is their own choice.’ (Lyn, CEO)

‘Lines in the sand’ that define limits of acceptable practice

Participants talked about groups preserving their independence by having careful processes around funding decisions and incorporating specific rules that defined the limits of acceptable behaviour. Decisions about funding, including pharmaceutical industry sponsorship, were generally made by group Boards and the CEO. Some groups had formal policies about working with industry that helped to guide decision-making processes.

This aimed to promote consistency in outcomes and helped CEOs to act in line with their Boards without necessarily having to take each decision back for wider discussion. Other participants described less formal decision-making processes through group discussions on a case by case basis. Policies and informal decision-making processes were informed by a range of sources, most prominently two industry-affiliated resources (the industry trade organisation’s Code of Practice49 and a document cobadged by industry and a national health consumer body26 but also one or more of personal philosophies of key staff entrenched in the organisational culture and member views about pharmaceutical industry interactions.

Many participants, both with and without formal policies, alluded to informal rules or ‘lines in the sand’ (Paula, CEO) that defined the group’s acceptable decisions and practices on industry funding. Together they represent prominent ethical issues for industry funding around which patient group practices and concerns coalesce.

Participants talked about these rules as defining limits of ethical practice, beyond which their group would not step. As such these rules constituted guidance for ethical decision making. They were not necessarily straightforward: for example, although the lines were generally presented as rigid, as in ‘we will do x but not y’, participants also described legitimate circumstances whereby y would be acceptable. We identified five dominant topics representing such ‘lines in the sand’ These were sponsor exclusivity, branded product marketing, agenda setting, advocacy and content of group activities. No participants discussed all five, but most explicitly or implicitly described one or more. We searched for, but did not find, any clear patterns between participant roles or organisational characteristics and their comments on each topic. Within each theme, we identified several places where different groups drew their line, such that some groups adopted a wider set of acceptable practice than others (see figure 1 and table 2). Box 1 provides an illustrative case study with additional case studies available in online supplemental file 4.

Figure 1 Patient group practices to protect against undue influence from pharmaceutical industry sponsors: dominant themes and variation in practice.
Table 2  Patient group practices to protect against undue influence from pharmaceutical industry sponsors: dominant themes and variation in practice

<table>
<thead>
<tr>
<th>Patient group practices</th>
<th>Example quotes from participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor exclusivity</strong></td>
<td></td>
</tr>
<tr>
<td>Will not accept exclusive (single company) sponsorship</td>
<td>‘Why would you just work with one company? That’s giving out all the wrong messages.’ Felicity, CEO</td>
</tr>
<tr>
<td>Has restrictions on accepting exclusive (single company) sponsorship, for example, only for small projects and/or clear fee for service</td>
<td>‘I’ve got a [big] meeting coming up soon and a couple of companies wanted exclusively me to go to them [for registration and travel funding] and I said, ‘No, I feel uncomfortable’ … It’s better if it’s funding from all of them rather than just one … There’s one company that’s offered me to go [on] another [short] trip … I accepted that flight because they want me to do a presentation there … otherwise normally no.’ Emily, CEO</td>
</tr>
<tr>
<td>Will accept exclusive (single company) sponsorship without restriction</td>
<td>‘Now we really have maybe one or two serious [Pharma] companies only… at the moment it’s only one actually.’ Neil, CEO</td>
</tr>
<tr>
<td><strong>Brand-marketing</strong></td>
<td></td>
</tr>
<tr>
<td>Will not mention branded products</td>
<td>‘When you’re talking about any particular drug effect you talk about the generic not the brand.’ Irene, CEO</td>
</tr>
<tr>
<td>Will not mention branded products to the public; will allow company ads for branded products in patient group magazine aimed at primary care practitioners</td>
<td>‘We have a policy of not promoting specific brands. We don’t promote any products. We have a policy if patients come to us, asking about products, we never actually give advice. We only give advice about general factors or lifestyle … We do accept in our GP magazines, the advertisement from some companies about their products, but that comes without any endorsement from [our group] and it comes directly from the company so this is fairly transparent.’ Neil, CEO</td>
</tr>
<tr>
<td>Will mention branded products to the public on request</td>
<td>‘We don’t mention the brand names in any of our written material [but] people call us and say, ‘Oh, what product is that?’ And we’ll say, ‘Well, there’s (Branded Product 1), there’s also this, there’s also that.’ So we do—we try to help people without pushing a particular line.’ Ian, CEO</td>
</tr>
<tr>
<td><strong>Agenda setting</strong></td>
<td></td>
</tr>
<tr>
<td>Will not accept funder-initiated projects</td>
<td>‘Pharmaceutical funding is a bit of a last resort so we use it where we can’t get money to do things that have already been strategically planned out. So if pharma comes to us and says, hey how about this project, that doesn’t happen.’ Gina, Board member</td>
</tr>
<tr>
<td>Will accept and consider funder-initiated ideas with restrictions</td>
<td>‘I’m also open to pharmaceutical companies coming to me with ideas … but I’m only interested in partnerships with Pharma if we’re there from the outset and if we are the ones who are managing the project.’ Robyn, CEO</td>
</tr>
<tr>
<td>Will always accept and consider funder-initiated ideas</td>
<td>‘Sometimes [the projects are] initiated by us…and in some cases it’s them contacting us about a specific initiative that … they’ve got underway and want us to be involved in.’ Lyn, CEO</td>
</tr>
<tr>
<td><strong>Funder involvement in patient group advocacy</strong></td>
<td></td>
</tr>
<tr>
<td>Will not allow funder to influence group’s advocacy</td>
<td>‘You can’t have a situation where Acme Pharmaceuticals is paying [their Public Relations people] to write [your] media release… that just gets you into trouble … where someone is drafting a press release for you, then you just get herded.’ Chris, Board member</td>
</tr>
<tr>
<td>May act independently on industry prompts about advocacy</td>
<td>‘If a company approaches us that they’ve got a new drug coming up for the Consumer Commission [drug regulator] then we leak it out to our consumers on the day, ‘this is what it is, this is what it does, here’s some information about it, if you’d like to make a submission, you know, please do’ … And if we think it’s a good thing we do a very brief submission ourselves.’ Irene, CEO</td>
</tr>
<tr>
<td>May cobadge advocacy submissions to government or media with industry funder</td>
<td>‘Sometimes a Pharma and if we’ve got a good relationship with them and they’re not—say for example recently one of the [disease a] drugs got PBS listing [author note: government subsidy through the Pharmaceutical Benefits Scheme] and we were happy to be quoted to say like, the incidence of [disease a] is blah-blah-blah, but not endorsing their drug so, that was fine.’ Irene, CEO</td>
</tr>
</tbody>
</table>
Risks and benefits of accepting industry funding

The participant cohort included people affiliated with groups that did not accept pharmaceutical industry money. These participants considered that any industry funding would present a risk to their independence. For example, Helen (CEO) explained that this might mean the group would have to act in ways that the company dictated:

‘The minute you introduce Big Pharma or any of the other big multinational players, there is a threat to your independence or on your ability to take a particular position because you may have to sing or dance to their tune.’

As such, in order to remove the risk of influence these groups refused any pharmaceutical company money.

For others, industry funding was not necessarily their preferred option, but a pragmatic solution to budgetary pressures. For example, Alan (CEO) alluded to the risks of associated with industry funders, but was willing to accept the money anyway since it was so hard to find alternative funding sources: ‘In an ideal world you’d say we’ll fund all this stuff without having any reference to [pharmaceutical industry] funders, but we don’t work in an ideal world … Funding is … difficult to get.’ Funding pressure was a particular issue for groups focused on lesser-known diseases where other sources of income, such as philanthropy, government or public donations, were more difficult to obtain. As Emily (CEO) explained, ‘it’s very competitive out there. I mean it’s, for a small organisation like us, and people haven’t heard of the disease before and they don’t care unless it affects them, why would they worry? You know? It doesn’t affect them.’

For many participants, the limited funding options available to patient groups meant they had to accept the inherent risks associated with pharmaceutical industry sponsorship in order to stay solvent.

Transparency

Transparency was described by participants as being an important element of independence, particularly perceived independence. Participants said that being open to members about where money was coming from was a necessary practice and the right thing to do. Dominant reasoning here was that the group should to give due credit to their sponsors and that groups should protect their integrity by being up front about accepting money from companies. None of the participants talked about transparency around funding in the context of assisting members or the public to assess any possible bias from funder influence. We did not discern any particular patterns among the patient group characteristics (funding status, disease/pathological process, geographic

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient group practices</strong></td>
<td><strong>Example quotes from participants</strong></td>
</tr>
<tr>
<td>(Reported about others) Funder directly shapes the group’s advocacy agenda</td>
<td>‘I do know that some health consumer organisations in the past and now, are funded by pharmaceutical companies and then lobby for medications to be listed on the PBS [for government subsidy]. We’ve never done that, never.’ Robyn, CEO</td>
</tr>
<tr>
<td><strong>Funder influence over content of patient group activities</strong></td>
<td></td>
</tr>
<tr>
<td>Will not allow funder input into content</td>
<td>‘We’re very deliberate in having an independent editorial with our [patient group] magazine. So Pharma do fund a little bit of that, money goes towards our [magazine] editorial but we make sure that there is no, they don’t sit in any of our editorial committees, they don’t get a say in what we do or print.’ Kevin, Board member</td>
</tr>
<tr>
<td>Will not allow funder input into content of formal educational event; companies can fund and market products to health professionals at educational fringe</td>
<td>‘We offer sponsorship packages [to the pharmaceutical companies for educational events] … There’s two different days that we do, one is for allied health professionals and one is for GPs. The allied health professionals, the pharma companies aren’t that interested in because they don’t have prescription pads, and the GP seminar days are the one that they have much more interest in … They come on the day, have a stand, have their information.’ Sally, CEO</td>
</tr>
<tr>
<td>Potential for funder influence over content through medical experts who may themselves accept industry money</td>
<td>‘We have … scrutiny from our medical scientific committee, which is, as I said, 12 people who represent different specialities… they all declare their conflicts of interest’ Neil, CEO</td>
</tr>
<tr>
<td>Will consider requests from funder to alter content</td>
<td>‘We’ve got [a new booklet] at the moment that we’re working on, we developed that in collaboration with some health consumers, the health professionals, the health educators … When we’re absolutely happy with it I [will] give it to the [pharmaceutical industry] partner to look at and they will, if they come back with any suggestions they understand that it is at the discretion of [our patient group] if we accept what their suggestions might be.’ Robyn, CEO</td>
</tr>
</tbody>
</table>

CEO, Chief Executive Officer; GPs, General Practitioners.
Box 1 Case study illustrating practices for working with pharmaceutical industry sponsors

Disease-specific patient group, high level of funding from pharmaceutical industry, no formal policy (Irene, CEO)

The patient group that Irene works for has ‘quite longstanding relationships with many of the pharmaceutical companies built up over a number of years’ particularly ‘to develop patient or primary care resources’ such as primary care workshops for general practitioners and nurses. The group does not have a formal policy about working with industry.

Sponsor exclusivity: The larger educational events tend to be funded by multiple companies, ‘so if it’s a big event… we combine together so if it’s going to be a $A70 000 project then, we might need two or three of them to come together.’ However, the group does allow companies to have exclusive sponsorship if they wish, ‘we got a big grant from one company for [a new project] so it all depends what they’re interested in and how excited they get about a project.’

Brand marketing: Irene’s group allows sponsoring companies to display ‘their logo on a [patient group] document’ and at the beginning of funded educational events but the speakers don’t mention branded products: ‘We recognise [funders] at the beginning saying ‘this has been supported by whoever’ but … we know the rules, we don’t talk about their drug, it’s more the class of the drug. If we’re talking about benefits of a particular drug, we never say the drug that the pharmaceutical company makes. It’s all very above board and done properly.’

Agenda setting: Irene’s group takes pharmaceutical company interests into account when deciding on their agenda: ‘We try and make [our events] educationally based because that’s the sort of thing that [companies] are interested in because obviously it reaches both health professionals and consumers which is probably what [companies] would be interested in.’ The group is also willing to discuss pharmaceutical company ideas for particular activities.

Advocacy: The group will consider company requests for joint advocacy. They were happy to be quoted on a company’s media release about a drug that had just received government subsidy noting that ‘it was something that was out there in the market already, it was a good thing.’ They are also happy to pass information on to their members from pharmaceutical companies that had new drugs coming up for government review for approval or subsidy, and encourage members to make supporting submissions. They did not, however, agree to a recent company request for them to endorse a ‘new drug’s that’s only in phase two trials at the moment…[because] it was just too much, it didn’t sit right.’

Content: Pharmaceutical companies have no influence over the content of the educational events, which are run by medical specialists, often without any patient group personnel attendance.

jurisdiction) and whether the organisation had transparency policies or practices in place.

The form and extent of described transparency practices was highly variable (see box 2). For example, only some participants said that their groups actively informed members about financial interactions with the pharmaceutical industry. Other participants explained that their group relied on companies to declare their spending on patient groups, talking about the industry trade organisation’s Code of Practice, which stated that member companies must publicly disclose their donations to patient groups. None of these participants talked about the limitations around these declarations or the lack of transparency around sponsorship from non-member companies.

Some of the more limited forms of transparency that participants talked about meant that it was unlikely group members, let alone the general public, would know about the links between the group and pharmaceutical companies. Some participants acknowledged this: for example, Sally (CEO) stated that her patient group members ‘probably aren’t aware that we’re connected to [pharmaceutical companies].’ However these participants generally felt that their members would be in favour of them accepting pharmaceutical industry money, so inadequate transparency practices did not trouble them unduly.

A minority of participants discussed the tension between transparency and promotion, realising that their group’s public declaration of company funding could deliver promotional marketing for the company. For some, this was deliberate. For example, Tegan (CEO) explicitly promised wide exposure to her pharmaceutical sponsors, ‘I say that we will put your logo on our programs and on our Facebook page and on our Instagram and our Powerpoint slides on the day, just to let them know that we’ll be publicising their company as being a sponsor.’ Others were concerned that naming of sponsors might be seen by the public as patient group endorsement of company products. That is, while it was widely seen as important to acknowledge industry funding, some participants recognised that this might be perceived as a stamp of approval for the funding company and their relevant products, although that was not the intended message from the patient group.

Box 2 Varying transparency practices adopted by patient groups around pharmaceutical industry funding

► Annual reports: The patient group’s annual report includes information on pharmaceutical industry sponsors, including one or more of: funder name, amount of money, use of money; the annual report may or may not be publicly available to non-members

► Annual personal declarations: The group’s personnel (eg, Board members, expert medical advisors) are required to make annual declarations about personal receipt of pharmaceutical industry funds, including one or more of: funder name, amount of money, what services or activities the money was paid for; this information may or may not be publicly available to non-members.

► Timely declarations: Receipt of pharmaceutical company funding by group or group personnel is declared at the time of activity or decision making, for example, at industry sponsored educational events, on industry sponsored information booklets, at committee meetings of staff and expert medical advisors.

► Public policy: The patient group’s policy around working with pharmaceutical company funders is available on the group’s website; this may or may not be publicly available to non-members.

► Accessibility: The policy and sponsorship details are highly visible, and readily available, within few ‘clicks’ on the website, including to non-members.

► No transparency detail: Group does not provide any detail about industry sponsors beyond company names or logos.
Transparency within the company was also discussed by participants. Patient group Board and expert committee meetings typically began with a request for attendees to declare any conflicts of interest. It was common for individuals to declare involvement in research and abstain from any related decisions (eg, around patient group funds being used for that research), but no participant could recall ever hearing Board members or experts declare receipt of pharmaceutical company money as a financial conflict of interest when discussing patient group agenda setting or other activities. That is, while it was usual practice for groups to be upfront about receiving company money, either through their own or the funding company’s transparency declarations, it was not front of mind to consider that colleagues or the public would want to know about industry sponsorship of key individuals within the patient group.

**DISCUSSION**

**Statement of principal findings**

Participants in this study described how the patient group sector receives pressure from pharmaceutical company funders to act in ways that prioritise company interests over their group’s interests. This places patient groups that accept industry money at risk of losing their independent voice. Participants were variably aware of this risk but acutely aware of public perception of perceived influence. They described how groups worked to try and protect their public credibility and their ability to act in ways of their own choosing rather than to meet the needs of their sponsor. Many industries, including the pharmaceutical industry, use a Code of Conduct approach to outline their expectations for ethical behaviour among their members. Using the insights from the discipline of applied ethics in this way we identified participants’ views on the limits of ethically acceptable behaviour. We found that there were some dominant ethical topics that participants talked about but there was little consensus around what constituted an acceptable behaviour limit or ‘line in the sand’. Some practices fell short of what others would regard as necessary safeguards, suggesting that groups using more lax restrictions were vulnerable to the very real threat of industry influence. Participants also described how the patient group sector saw transparency about financial interactions between patient groups and pharmaceutical companies as important but not necessarily for the reasons discussed in the healthcare literature on commercial influence in health. Transparency was seemingly more about giving due credit to sponsors than about alerting the public to risk of bias or prompting disengagement from industry. Ways of declaring industry funding were variable, sometimes inadequate. In particular, there was an over-reliance on industry declarations, which may be hard to find, lacking detail or absent altogether. There was limited recognition of the importance of transparency around industry funding of key individuals within or advising patient groups. Such practices mean that the public are unable to make informed assessments about the risk of bias over the activities of groups that accept industry funding.

**Strengths and limitations of the study**

Ours is the first Australian study we are aware of that identifies the broad range of day-to-day practices that patient groups actually use to mitigate against undue actual or perceived influence from pharmaceutical industry funders. It builds on other studies that provide information on practices in different countries. This information is important because it allows public scrutiny and enables identification of best practice. This study was limited to the Australian setting; groups in other jurisdictions may have different levels of regulation or guidance. Nevertheless, the results are likely to have global relevance since there is international evidence that many patient groups accept pharmaceutical industry funding.

Although we spoke with diverse participants affiliated with a range of groups we did not cover all types of patient groups and did not speak with individual patient advocates unaffiliated with a patient group so we may have missed some issues or ideas. In addition, given that those we did interview held senior positions, the participants may have been experienced in managing the expectations of the public (including interested researchers) about their group’s relationships and interactions with industry, and delivered information that supported the concept of an independent patient group sector. However, participants appeared to speak candidly about their experiences and views and we did hear a range of perspectives about the industry, including positive, negative and unsure, as described in our previous paper from this study.

**Correlation with existing literature**

Our finding that some patient group personnel experience pressure from pharmaceutical industry funders correlates with results from other studies. This suggests that at least some companies use money to seek influence over patient groups in ways that prioritise commercial over patient group interests. It means the sector is vulnerable to the kind of high level dependence that Marks describes, whereby industry funding generates overt or subtle reciprocities from patient groups. Many industries, including the pharmaceutical industry, use a Code of Conduct approach to outline their expectations for ethical behaviour among their members. Using the insights from the discipline of applied ethics in this way, we describe participants’ views on the limits of ethically acceptable behaviour. We found that there were some dominant ethical topics that participants talked about but there was little consensus around what constituted acceptable behaviour limits or ‘lines in the sand’.

The concept of ‘lines in the sand’ describes the kinds of rules that patient groups are using to navigate the challenges of industry funding. The lack of a consistent, independent approach is concerning for the sector. Some patient group personnel feel immune to undue influence
from pharmaceutical industry funders, in the same way that health professionals regard themselves as with-
standing industry influence. Evidence suggests, however, that people can be unconsciously influenced by even small
amounts of money. For example, gifts from pharmaceu-
tical companies can influence clinician prescribing,51 52
and drug and device industry funded research is more
likely to deliver outcomes that are favourable to the
sponsor than research funded by other sources.22 Patient
groups that feel immune to influence because of a
perceived lack of power as non-prescribers echo the views
of non-prescribing nurses. However, nurses are important
marketing targets for pharmaceutical companies because
of their extensive impact over treatment and purchasing
decisions in hospitals,53 and similarly patient groups
can be useful to companies because of their impact on
drug use through disease awareness, research and drug
advocacy.

Previous studies on how patient groups manage
conflicts of interest around pharmaceutical funders have
concentrated mainly on transparency around funding
and policy. These show that some, but not all, patient
groups disclose industry funding6 9 14 32 33 and a minority
have publicly available conflict of interest policies.5 32
Our results corroborate these studies and we also provide
detailed information on practices used by some patient
groups to reduce the risk of undue influence from phar-
macetical sponsors.

Implications for policy and practice
Much of the literature around patient group interac-
tions with the pharmaceutical industry discusses the
importance of codes of practice authored by industry
and/or patient groups, to guide and manage financial
relationships. Highlighted issues often include rules
around agenda setting, funding diversity and transpar-
ency. Our work shows that patient groups are listening to
this advice, and many are adopting particular practices
around these topics. However, our work also suggests that
rules might not always be sufficient protection against
the risk of industry influence, since some groups are
adopting practices that others are likely to consider inad-
equate. In addition, promoting a rule-based ‘solution’
for patient group–industry interactions presupposes that
any perceived ‘problem’ with industry funding in the
patient group sector stems from inadequate guidance or
regulation. Other ways to frame the problem (and subse-
quently address the solution) are largely ignored but
could include: lack of separation of powers within patient
groups (fundraiser, advocate, educator) and lack of alter-
native funding sources.

Separation of powers has been championed by Rose34
and Marks8 who each advocate for maintaining strict
separation within patient groups between fundraisers and
those who set the agenda, write communications and drive
policy. They argue that personnel who build strong rela-
tionships with industry funders are more likely to feel the
social pressure of reciprocity and may be more favourably
predisposed towards company policies and practices.
Separating fundraising duties from patient group execu-
tive duties may help to ameliorate this possibility. Ideally,
groups would also separate out governance duties to a
different committee who would monitor practices and
evaluate outcomes around pharmaceutical company
interactions.34 These ideas challenge the traditional setup
of patient groups, whereby Board members and the CEO
tend to be responsible for building and reviewing funder
relationships and writing group agendas and policies,
and separate governance committees are non-existent.
Rose herself acknowledges that paucity of funds and staff
in many smaller patient groups will make her recommen-
dations difficult to put into practice, but they remain an
important conceptual standard.

Another way of separating policy-makers from interac-
tions with pharmaceutical industry personnel could be to
to enforce a shared corporate pool of funds5 via a tax on
industry profits or based on a percentage of marketing
spending.56 This, however, would not address the under-
lying issue of agenda distortion that might arise from the
patient group sector relying on a commercial industry
with a particular set of priorities around drugs and drug
policies.8 30 That is, even if a group has separation of
powers as a way to protect against undue influence from
pharmaceutical industry funders, they might still be cognis-
ant of prioritising activities and advocacy that appeal to
future industry funders (eg, focus on educating health
professionals rather than patients, or on long-term struc-
tural change) and neglect those that run directly counter
to future industry funders (eg, drug safety, preventing
overdiagnosis and overtreatment).34

Participants described varying approaches to prac-
tices with a clear potential for undue influence, such as
sponsor involvement in shaping advocacy, information
materials and educational content. This was despite
Australia’s industry Code of Practice24 49 and the joint
guidance from industry and a health consumer group.96
This may reflect the guidance document focus on general
principles rather than practical suggestions, and industry
involvement in developing codes.

An alternative is complete disengagement from the
pharmaceutical industry.7 This would entail recognition
of the inadequacy of alternative funding sources, and
require increased support from other potential funders
such as governments, with an understanding that patient
support and a patient voice are important components
of national healthcare services. Disengagement from the
industry would build more public surety about patient
group sector priorities being patient issues rather than
commercial interests.

Unanswered questions and future research
We do not know the best way for patient groups to
remove the risk of pharmaceutical industry influence but
still receive company money, or if this is even possible.
Some groups have taken the bold step of complete
independence from pharmaceutical industry funding.
Even so, there may be residual industry influence in the sector if groups whose interests naturally align with pharmaceutical companies are preferentially funded and empowered.¹⁶ Future developments should not be led by pharmaceutical industry sponsors alone. We recently worked with peak bodies to convene a stakeholder meeting of patient groups to discuss the risks and benefits of accepting pharmaceutical funding, and to share ideas and resources about how best to proceed into the future. ⁴⁶ ⁴⁷ This meeting was a step towards addressing the need for independent, sector-wide guidance with resources that support and inform patient group policies and practices to mitigate against pharmaceutical industry funder influence.

CONCLUSIONS

Information about how patient groups protect themselves against undue influence from pharmaceutical industry funders is important because it allows public scrutiny and conversation about the adequacy of such practices. There is insufficient empirical research around which practices are most effective. Inadequate strategies may mean that pharmaceutical funders are influencing patient group activities in ways that do not necessarily prioritise the interests of group members or the wider public. Transparency around patient group acceptance of pharmaceutical industry money remains patchy, hampering the public’s knowledge about possible links between industry sponsorship and patient group activity. Industry influence over all the key stakeholders in healthcare should be explored and contained in order to maintain a health sector that prioritises the public’s health.

Twitter Quinn Grundy @QuinnGrundy

Acknowledgements We thank all the individuals who took time to participate in our interviews. We also thank E Karanges and S Swandari for their contributions towards building the database of industry payments to patient groups.

Contributors LP designed the study, collected the data, participated in the analysis and wrote the first and subsequent drafts of the manuscript. AF, QG, BM and LB participated in the design, data analysis and commented on all drafts, including reading and approving the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. LP is the guarantor.

Funding No specific funding was received for this study. QG was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research. AF was supported as a post-doctoral fellow by the National Health and Medical Research Council of Australia (NHMRC), project grant no.1122332.

Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years. BM is a member of the European network of Health Action International (HAI-Europe). All other authors declare no other relationships or activities that could appear to have influenced the submitted work.

Patient consent for publication Not required.

Ethics approval The study was approved by The University of Sydney Human Research Ethics Committee (project number 2017/758).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. The database of publicly declared industry payments to patient groups is available at: https://researchdata.ands.org.au/pharmaceutical-industry-funding-december-2016/1330638

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Lisa Parker http://orcid.org/0000-0001-8635-8953
Quinn Grundy http://orcid.org/0000-0002-7640-8614
Barbara Mintzes http://orcid.org/0000-0002-8671-915X
Lisa Bero http://orcid.org/0000-0003-1893-6651

REFERENCES


10 Batt S. Who will support independent patient groups? BMJ 2014;349:g6306.


28 Jones K. In whose interest? relationships between health consumer groups and the pharmaceutical industry in the UK. SocioL Health Illn 2008;30:929–43.


Supplementary File 1

Body systems
Respiratory
Neurological
Cardiovascular
Renal
Gastrointestinal
Sensorineural
Dermatological
Musculoskeletal
Women’s health
Mental health
Haematological
Endocrine

Pathological processes
Immunological
Infection
Genetic
Cancer
Degenerative
Inflammatory
Endocrine
Vascular
Trauma
Toxic
Metabolic
General topics for semi-structured interviews

1. **Contextual information about the group** – eg main focus, aims and scope, main activities, size

2. **Interviewee’s role within the group** – eg staff or volunteer, length of time associated with the group, experience within the group, role and activities

3. **Funding of the group** – eg regular funders, funding activities, previous funding patterns, challenges associated with obtaining funding

4. **Pharmaceutical funding, what happens & how it happens**
   - current and previous pharmaceutical funders
   - mechanics of funding eg how did it start, personnel involved, how is the amount determined
   - type of funding eg donation, payment for advertising
   - other types of pharmaceutical support – eg pharmaceutical personnel on group executive, provision of conference venue, delivery of educational material

5. **Group activities related to pharmaceuticals** eg advertising, distributing information, public advocacy

6. **Pharmaceutical funding, group experiences and policies**
   - eg is there a policy about pharmaceutical funding
   - is there any discussion within the group about pharmaceutical funding
   - any differences of opinion?
   - is there any (real or perceived) pressure to conform to the interests of industry?
   - is there any pestering by industry reps or others about funding or contributing to the group in others ways?
Coding tree

Participant details - previous occupation/experience; role (CEO/director, other staff, Board)

Group details - location (local, national); focus (disease specific, health services); funding sources; involvement of pharma in group’s foundation

Interactions with pharmaceutical industry – how many companies; who initiates; relationships and who has power; what events are funded (what kinds, frequency); what other benefits or resources are provided by industry; what group gives to industry; companies overstepping the mark

What companies wants – views on why pharma is sponsoring you

Rules – personal or group rules on what you would / would not accept pharma funding for; Medicines Australia code of conduct

Reasons – why your group accepts pharma sponsorship; why your group doesn’t accept pharma sponsorship; why it might be different for other groups; responding to critics; in an ideal world would you accept pharma funding? (why/why not)

Independence – trust; perceived independence / brand; transparency
Disease specific patient group, mid-range funding from pharmaceutical industry, formal policy (Sally)

The patient group that Sally works for accepts money from pharmaceutical companies, “predominantly for … education events for … GPs [General Practitioners, primary care doctors].” The group recently adopted a formal policy about working with pharmaceutical funders.

**Sponsor exclusivity:** The group tends to have multiple pharmaceutical companies sponsoring their large GP events, but will accept solo sponsorship for smaller events, “so last year we [went to a rural town] and we took a [specialist] in [to speak to the GPs] and we were sponsored by [one pharmaceutical company] to do that, which was great.”

**Brand marketing:** Sally’s group allows pharmaceutical sponsors to provide branded product marketing information to health professionals who attend educational events, “[Pharmaceutical reps] come on the day, have a stand, have their information.” The group does not allow companies to promote their branded products to the public: “[Members of the public] don’t come to an event where there’s a stand and there’s a pharmaceutical rep present.”

**Agenda setting:** The group works hard to prevent pharmaceutical company sponsors having undue influence over its agenda and according to Sally the new policy was adopted with that intention: “We’ve put a policy in place last year, that I got the board to approve saying … we won’t do anything that we weren’t planning on doing in the first place just because a pharmaceutical company has asked us to.” Sally explained why she drafted this policy: “I was just concerned with the pharmaceutical companies that the direction of what we were doing might be influenced too much, so it was just a clarification from my part to say, ‘That’s not what we’re here for, we’re not going to be mouthpieces for anybody, we’re allowed to push our agenda.’ … I think, if you don’t have policies in place early on to make it really clear what you will and won’t accept, then it makes it really difficult to say no.” As a result of this new policy, Sally said she has more easily been able to reject pharmaceutical company initiated project ideas: “One of the pharmaceutical companies - recently I was talking to them about sponsorship for [an education project] which they weren’t interested in, but they did say they would be interested if we could send them out to talk to GPs about this specific disease, which is obviously the one that they’ve got the specific medication for … This policy is great because it’s now very clear what we can and can’t accept … I can say quite clearly, ‘Well, no, that wasn’t our intention, so we can’t accept that sponsorship, but if you want to make it a general sponsorship, then we can talk about it.’ So it just makes it easier from my point of view, it stops any time wasting or confusion … if it sits within [the policy], we accept it and if it doesn’t, then we don’t, we don’t have to think about it every single time.”

In general, Sally prefers non-pharmaceutical corporate sponsors because she thinks it is more obvious that the purposes of non-pharmaceutical sponsorship are marketing, “it’s very transparent … [For example] an electrician company and they wanted to have our logo on the back of their trucks because it made people think they were nicer than the other electrical companies.” In contrast, Sally thinks that pharmaceutical company sponsorship of patient groups is often presented as being non-promotional and she thinks this is misleading: “No matter how much they say they’re not there to sell their product, obviously clearly they are.”
Disease-specific patient group, high level of funding from pharmaceutical industry, formal policy (Paula)

The patient group that Paula works for accepts industry money for big programs of activities and for small individual projects: “the industry support really allows us to develop patient resources, [primary care] training, advocacy and awareness across different disease areas.” The group has a formal “working with industry” policy, available on their website, which provides “agreed guidelines for working together …It just is a way for us to articulate for new staff coming in or for new industry partners about what the relationship should be.”

**Sponsor exclusivity:** The group accepts exclusive sponsorship but only for small projects: “We have no [big] program area that has one sponsor and that’s one of our lines in the sand. For individual projects, I can’t tell you we’ve never done it, I think we did a [small activity] that was supported by one particular company … but we would always aim to work with more than one company.”

**Brand marketing:** The group allows sponsoring companies to advertise to health professionals and sees this as part of transparency around funding. They sometimes put patients in direct contact with pharmaceutical companies to facilitate industry staff knowledge of the patient perspective: “Often [companies will] come to us and say ‘We’re training our sales group’ and … [ask us to] approach a patient to go and speak to the staff of the company.”

**Agenda setting:** Paula’s group provides opportunities for existing pharmaceutical company sponsors to suggest activities and will consider each idea on its merits according to whether or not it fits with the group’s strategic plans: “Once we are in a partnership with a company, they may well come to us and say, ‘We had an idea for something and we’d like to partner with you on this.’” Representatives from sponsoring companies are also invited to the group’s annual agenda planning meeting: “They’ll get to come in, raise issues.”

**Advocacy:** The group is willing to consider pharmaceutical company requests for patient group advocacy in support of the company’s application for government subsidy of its products. They might accept company advice on disease awareness campaigns: “They have great suggestions in terms of how we market ourselves, how we raise awareness.” However, the group will not automatically accept a company’s ideas or requests for advocacy if they are not part of the group’s “overall strategy” and the group is guided by the principle that “everything goes through the patient lens and through the evidence lens.” Paula notes, “We certainly have been in a situation where we have not been able to [advocate in] support applications of industry partners for [government] reimbursement for particular treatments if the evidence isn’t there.”

**Content:** Sponsoring companies have “no involvement in the program or who the speakers” are” at educational events. The group’s clinical guidelines are authored by medical experts. Paula stated, “I know that the chair of our guideline committee has no links with industry but we don’t have a policy for the members. It’s probably a good idea actually.”